You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業(02616.HK)與Blueprint啟動治療肝細胞癌患者的Ib/II期臨床試驗
阿思達克 01-07 09:57

基石藥業(02616.HK)公布,公司與Blueprint Medicines,即一家專注於探索具有特定基因特徵的癌症、罕見病及癌症免疫療法的精准治療的公司,共同宣佈fisogatinib(一款對致癌驅動因數具有高選擇性的藥物)聯合CS1001治療局部晚期或轉移性肝細胞癌(HCC)的Ib/II期試驗已完成首例患者給藥,研究將在中國的多個臨床研究中心開展。

公司指,此項試驗將評估靶向治療和癌症免疫治療聯合在局部晚期和轉移性HCC患者中增強抗腫瘤活性的潛力。fisogatinib是由BlueprintMedicines開發的一款在研的強效、高選擇性成纖維細胞生長因數受體-4(「FGFR4」)抑制劑,用於治療FGFR4驅動的晚期HCC。CS1001是一款由基石藥業開發的、針對多個癌種的在研抗PD-L1單克隆抗體。臨床前研究表明,fisogatinib可以刺激T細胞浸潤到腫瘤微環境中,這提示fisogatinib聯合抗PD-L1抑制劑將有可能在FGFR4驅動的晚期HCC患者中展現出更強的療效。

公司已與BlueprintMedicines達成獨家合作及授權協議,獲得了包括fisogatinib在內的三款候選藥物在中國大陸、香港、澳門及台灣的開發與商業化權利。Blueprint Medicines保留在世界其他地區開發及商業化這三款候選藥物的權利。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account